[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metastatic-kidney-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metastatic-kidney-cancer":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100410361","an-investigation-of-kidney-and-urothelial-tumor-metabolism-in-patients-undergoing-surgical-resection-andor-biopsy-100410361",false,"NCT04623502","An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and\u002For Biopsy","Inclusion Criteria:\n\n* Patients must have radiographic evidence of known or probable kidney or urothelial cancer requiring surgical biopsy or excision.\n* Age ≥ 18 years\n* Subjects of all races and ethnic origins\n* The willingness to sign and ability to understand a written informed consent.\n* Patients participating in other clinical trials are eligible, and will be evaluated on a case by case basis by the Principal Investigator, Dr. Vitaly Margulis, MD.\n\nExclusion Criteria:\n\n* Uncontrolled or poorly controlled diabetes for patients receiving a 13C infusion\n* Pregnant or breastfeeding\n* Not a surgical candidate",true,"ALL","18 Years",{"count":19,"type":20},600,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to understand the metabolism of cancers involving the kidney, including renal cell carcinomas and urothelial cell carcinomas, and how kidney cancers use different types of fuel to support tumor growth. This study uses specially labeled nutrient tracers of compounds normally found circulating in the blood. The nutrients (glucose, fructose, glutamine, acetate, and lactate) are also found in common foods. A nutrient tracer will be given to the participants through an intravenous (IV) catheter during surgery or biopsy, and blood will be collected every 30 minutes during the infusion to monitor safety parameters and the nutrient tracers. The investigators will collect a tissue sample after the completion of surgery. Participants not having an infusion will have their tissue collected after surgery or biopsy.\n\nParticipation in this study will not change patient care. All patients will receive standard of care treatment as determined by their doctors.",[26,27,28,29,30,31,32,33,34,35,36,37],"Kidney Cancer","Renal Cell Carcinoma","Clear Cell Carcinoma","Urothelial Carcinoma","Metastatic Kidney Cancer","Metastatic Urothelial Carcinoma","Papillary Renal Cell Carcinoma","Chromophobe Renal Cell Carcinoma","Fumarate Hydratase Deficiency","Succinate Dehydrogenase-Deficient Renal Cell Carcinoma","HLRCC","Hereditary Leiomyomatosis and Renal Cell Cancer","RECRUITING","2026-01-27",{"date":41,"type":42},"2026-01-28","ACTUAL",{"date":44,"type":42},"2019-09-30",{"date":46,"type":20},"2027-09-30",{"name":48,"class":49},"University of Texas Southwestern Medical Center","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":21,"phases":62,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":50},"100500493","phase-3-measuring-oncological-value-of-exercise-and-statin-100500493","NCT05796973","Measuring Oncological Value of Exercise and Statin","Syöpäpotilaan Ennusteen Parantaminen Muuttamalla syövän mikroympäristöä ja Metaboliaa Liikunnalla ja lääkkeellisesti - Measuring Oncological Value of Exercise and Statin","MOVES","Inclusion Criteria:\n\n* The patient has metastatic prostate cancer, breast cancer, ovarian cancer or kidney cancer confirmed histologically and by imaging, for which 1st-line cancer drug treatment is started\n* Prostate cancer: First course of docetaxel treatment or second-generation antiandrogen treatment for metastatic prostate cancer.\n* Breast cancer: First-line medical treatment of metastatic breast cancer regardless of hormone receptor status.\n* Kidney cancer: Kidney cancer, for which 1st-line cancer drug treatment is started as tki monotherapy and\u002For IO monotherapy or as a combination therapy.\n* Ovarian cancer: stage III or IV cancer for which chemotherapy treatment is started.\n* The patient agrees to the study and signs a written informed consent.\n* Adult (18 years=\\>) women (breast, ovarian and kidney cancer) and men (prostate and kidney cancer) are recruited for the study.\n* In women, the use of a reliable contraceptive during the intervention\n\nExclusion Criteria:\n\n* High risk of bone fractures\n* Inability to physical exertion and\u002For unsuitability for cancer drug treatment\n* Poor co-operation ability for psychological reasons\n* Active use of cholesterol-lowering drugs\n* Severe liver or kidney failure\n* Troublesome side effects that occurred in the past during cholesterol medication\n* Continuous use of medicinal substances that interact with atorvastatin during the study period\n* A special group of subjects according to the EU Clinical Trials Regulation 536\u002F2014 (e.g. pregnant or lactating women)\n\nExclusion criteria in patients who are already using statin medication before the study:\n\n* High risk of bone fractures\n* Inability to physical exertion and\u002For unsuitability for cancer drug treatment\n* Poor co-operation ability for psychological reasons\n* Severe liver or kidney failure\n* A special group of subjects according to the EU Clinical Trials Regulation 536\u002F2014 (e.g. pregnant or lactating women)","99 Years",{"count":61,"type":20},240,[63],"PHASE3","The aim of the study is to find out whether supervised physical exercise during cancer drug treatment improves the effectiveness of the treatment in metastasized breast, kidney, ovarian and prostate cancer compared to unsupervised exercise. In addition, the investigators are investigating whether the use of atorvastatin combined with guided group exercise training would further improve the response to cancer treatment.",[66,67,26,68,69,30,70,71,72,73,74,75],"Prostate Cancer","Breast Cancer","Ovarian Cancer","Metastatic Breast Cancer","Metastatic Renal Cell Carcinoma","Metastatic Renal Cancer","Metastatic Prostate Cancer","Metastatic Prostate Adenocarcinoma","Metastatic Ovarian Cancer","Metastatic Ovary Cancer","2025-06-23",{"date":78,"type":42},"2025-06-27",{"date":80,"type":42},"2023-03-31",{"date":82,"type":20},"2027-12-31",{"name":84,"class":49},"Tampere University Hospital",{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":93,"targetDuration":4,"studyType":21,"phases":95,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":113},"100544111","phase-3-care1-pragmatic-clinical-trial-100544111","NCT06364631","CARE1 Pragmatic Clinical Trial","First Line Randomised Study Platform to Optimize Treatment in Patients With Metastatic Renal Cell Carcinoma","CARE1","Inclusion Criteria:\n\n1. Histologically confirmed metastatic (AJCC Stage IV) renal cell carcinoma with a clear-cell component.\n2. Intermediate- or poor-risk mRCC as defined by IMDC classification.\n3. Adult male or female patients (≥ 18 years of age at inclusion).\n4. Karnofsky Performance Status (KPS) ≥70%.\n5. Adequate organ and marrow function, according to investigator assessment and\n\n   1. Absolute neutrophil count (ANC) ≥ 1000\u002FμL (≥ 1.5 GI\u002FL)\n   2. Platelets ≥ 100,000\u002FμL (≥ 100 GI\u002FL)\n   3. Hemoglobin ≥ 8 g\u002FdL (≥ 80 g\u002FL)\n   4. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN.\n   5. Calculated creatinine clearance ≥ 30 mL\u002Fmin (≥ 0.67 mL\u002Fsec) using the CKD- EPI equation\n6. Patient should understand, sign, and date the written informed consent form prior to any protocol-specific procedures performed.\n7. Patient should be able and willing to comply with study visits and procedures as per protocol\n8. Patients must be affiliated to a social security system or beneficiary of the same\n9. Female patients must either be of non-reproductive potential or must have a negative serum pregnancy test within 14 days prior to the administration of study drug. Childbearing potential women must have agreed to use one barrier method of contraception, such as condom, plus an additional highly effective method of contraception during treatment on this trial and for up to 5 months after the last dose of study treatment.\n10. Fertile men with a female partner of childbearing potential must agree to use one barrier method of contraception, such as condom, during treatment on this trial and for up to 4 months after the last dose of treatment. Their women of childbearing potential partner must agree to use a highly effective method of contraception during the same period.\n11. Female subjects of childbearing potential must not be pregnant at screening.\n\nExclusion Criteria:\n\n1. Prior systemic anticancer therapy for mRCC including investigational agents. Note: One prior systemic adjuvant therapy is allowed for completely resected RCC and if recurrence occurred at least 6 months after the last dose of adjuvant therapy.\n2. Uncontrolled brain metastases (adequately treated with radiotherapy and\u002For radiosurgery prior to randomization are eligible). Subjects who are neurologically symptomatic as a result of their CNS metastasis or are receiving systemic corticosteroid treatment (prednisone equivalent \\> 10 mg\u002Fday) at the planned time of randomization are not eligible.\n3. Concomitant oral anti-vitamin K anticoagulation. An exception is the use of LMWH or direct oral anticoagulants (DOAC), if considered safe by investigator assessment.\n4. The subject has uncontrolled, significant intercurrent or recent illness such as the following conditions:\n\n   a. Cardiovascular disorders:\n\n   i. Congestive heart failure (CHF) class III or IV as defined by the New York Heart Association, unstable angina pectoris, myocardial infarction, serious cardiac arrhythmias (e.g., ventricular flutter, ventricular fibrillation, Torsades de pointes).\n\n   ii. Uncontrolled hypertension despite optimal antihypertensive treatment.\n\n   iii. Stroke, or other symptomatic ischemic event or severe thromboembolic event (e.g., symptomatic pulmonary embolism \\[PE\\], incidental PE is acceptable if deemed safe by the investigator) within 3 months before randomization.\n\n   b. Active GI bleeding or symptomatic Gastrointestinal (GI) tract obstruction\n\n   c. Clinically significant bleeding including uncontrolled hematuria, hematemesis, or hemoptysis\n\n   d. Autoimmune disease that has been symptomatic or required immunosuppressive systemic treatment within the past two years from the date of randomization.\n\n   Note: Patients with a history of Crohn's disease or ulcerative colitis are always excluded\n\n   e. Any condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization.\n\n   Note: Inhaled, intranasal, intra-articular, or topical steroids are permitted. Adrenal replacement steroid doses \\> 10 mg daily prednisone equivalent are permitted. Transient short-term use of systemic corticosteroids for allergic conditions (e.g., contrast allergy) is also allowed.\n\n   f. Active infection requiring systemic treatment.\n\n   g. Major surgery (e.g., nephrectomy, GI surgery, removal of brain metastasis) within 4 weeks prior to randomization or serious non-healing wound\u002Fulcer\u002Fbone fracture.\n5. Pregnant or breastfeeding females.\n6. Any other active malignancy at time of randomization or diagnosis of another malignancy within 3 years prior to randomization that requires active treatment, except for locally curable cancers that have been apparently cured.\n7. Hypersensitivity to any of the active substances or to any of the excipients administered during the study\n8. Use of live vaccines within 28 days before randomization\n9. Persons deprived of their freedom or under guardianship, or for whom it would be impossible to undergo the medical follow-up required by the trial, for geographic, social or psychological reasons.",{"count":94,"type":20},1250,[63],"Systemic therapy for renal cell carcinoma (RCC) relies on 2 classes of agents: anti-angiogenic targeted therapy (Vascular endothelial growth factor Tyrosine Kinase Inhibitor- VEGFR TKI) and immune checkpoint inhibitor (ICI), targeting either PD1\u002FPDL1 axis or CTLA4. Combination therapy is SOC for clear cell RCC in all guidelines with either ICI-ICI or ICI-VEGFR TKI. However, no head-to-head comparison have been performed between the 2 approaches and patients are treated based on physician decision without clinical \u002Fbiomarker factors to guide treatment selection. PDL1 staining is, to date, the biomarker that has demonstrated its ability to enrich for overall survival benefit favoring ICI-ICI strategy in PDL1(+) and ICI-VEGFR TKI in PDL1(-) patients.\n\nStudy design has been developed to demonstrate that ICI-ICI is superior to ICI-VEGFR TKI in prolonging Overall Survival (OS) for PDL1(+) patients and to demonstrate that ICI-VEGFR TKI is superior to ICI-ICI in prolonging Progression Free Survival (PFS) and OS for PDL1(-) patients.",[30,98],"Metastatic Kidney Carcinoma",[100,101,102,103],"METASTATIC KIDNEY CANCER","METASTATIC KIDNEY CARCINOMA","PRAGMATIC CLINICAL TRIAL","PDL1","2025-01-14",{"date":106,"type":42},"2025-01-16",{"date":108,"type":42},"2024-04-12",{"date":110,"type":20},"2032-05-05",{"name":112,"class":49},"Gustave Roussy, Cancer Campus, Grand Paris",46]